Amplia Therapeutics (Australia) Today
| ATX Stock | 0.09 0 2.33% |
Performance0 of 100
| Odds Of DistressOver 84
|
Amplia Therapeutics is selling for under 0.088 as of the 30th of November 2024; that is 2.33 percent increase since the beginning of the trading day. The stock's last reported lowest price was 0.086. Amplia Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Amplia Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Amplia Therapeutics is entity of Australia. It is traded as Stock on AU exchange. The company has 358.24 M outstanding shares. More on Amplia Therapeutics
Moving against Amplia Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Amplia Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Amplia Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Amplia Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
Amplia Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Amplia Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsAmplia Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Amplia Therapeutics' financial leverage. It provides some insight into what part of Amplia Therapeutics' total assets is financed by creditors.
| |||||
Amplia Therapeutics (ATX) is traded on Australian Securities Exchange in Australia and employs 9 people. Amplia Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 31.53 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Amplia Therapeutics's market, we take the total number of its shares issued and multiply it by Amplia Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Amplia Therapeutics operates under Biotechnology sector and is part of Health Care industry. The entity has 358.24 M outstanding shares.
Amplia Therapeutics has accumulated about 7.98 M in cash with (5.13 M) of positive cash flow from operations.
Check Amplia Therapeutics Probability Of Bankruptcy
Ownership AllocationAmplia Therapeutics holds a total of 358.24 Million outstanding shares. Amplia Therapeutics shows 17.55 percent of its outstanding shares held by insiders and 18.05 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Amplia Ownership Details
Amplia Therapeutics Risk Profiles
Although Amplia Therapeutics' alpha and beta are two of the key measurements used to evaluate Amplia Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
Amplia Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Amplia Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Commodity Directory Now
Commodity DirectoryFind actively traded commodities issued by global exchanges |
| All Next | Launch Module |
Amplia Therapeutics Corporate Management
Elected by the shareholders, the Amplia Therapeutics' board of directors comprises two types of representatives: Amplia Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amplia. The board's role is to monitor Amplia Therapeutics' management team and ensure that shareholders' interests are well served. Amplia Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amplia Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hamish George | Chief Officer | Profile | |
| Benjamin Segal | Clinical Consultant | Profile | |
| BSc BSc | MD CEO | Profile | |
| Frank Gelder | Founding Scientist | Profile | |
| James Taylor | Trials Consultant | Profile | |
| TerrieAnne Cock | Head Biology | Profile | |
| Frederick Reno | Toxicology Consultant | Profile |
Additional Tools for Amplia Stock Analysis
When running Amplia Therapeutics' price analysis, check to measure Amplia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amplia Therapeutics is operating at the current time. Most of Amplia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amplia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amplia Therapeutics' price. Additionally, you may evaluate how the addition of Amplia Therapeutics to your portfolios can decrease your overall portfolio volatility.